Citation

Tao R, Emslie G, Mayes T, Nakonezny P, Kennard B, Hughes C. J. Am. Acad. Child Adolesc. Psychiatry 2009; 48(1): 71-78.

Copyright

(Copyright © 2009, American Academy of Child Adolescent Psychiatry, Publisher Lippincott Williams and Wilkins)

DOI

10.1097/CHI.0b013e318190043e

PMID

unavailable

Abstract

OBJECTIVE: Less than half of youths achieve remission (minimal to no symptoms) after acute antidepressant treatment. Early identification of who will or will not respond to treatment and achieve remission may help clinicians formulate treatment decisions and shorten the time spent on ineffective treatments. In a prospective open-label fluoxetine study, we investigate indicators of acute treatment response and remission.

METHOD: One hundred sixty-eight children and adolescents, ages 7 to 18 years, with primary diagnoses of major depressive disorder received 12 weeks of fluoxetine treatment. The youths were evaluated using the Kiddie Schedule for Affective Disorders and Schizophrenia. The outcome measure included the Children's Depression Rating Scale-Revised.

RESULTS: Positive first-degree family history of depression was the only baseline demographic and clinical characteristic that predicted a favorable treatment response (p =.01). The rate of symptom improvement, however, is a good indicator of acute treatment response. A significant symptom reduction (approximately 50%) by week 4 is needed to achieve remission at the end of acute treatment.

CONCLUSIONS: This study demonstrated that the rate of symptom improvement during early weeks of acute fluoxetine treatment is a good indicator of remission. Treatment approach may be reevaluated and modified as early as week 4 during acute treatment. © 2008 by the American Academy of Child and Adolescent Psychiatry.

Language: en

Keywords

adolescent; human; child; female; male; suicidal ideation; suicide attempt; major depression; suicidal behavior; clinical trial; disease severity; prediction; article; major clinical study; mental disease; antidepressant agent; fluoxetine; priority journal; childhood disease; psychopharmacotherapy; patient compliance; drug efficacy; drug withdrawal; rash; remission; Fluoxetine; psychological rating scale; treatment response; drug dose increase; Clinical Global Impression scale; Pediatric depression; Acute treatment; Children's Depression Rating Scale